Department of Rheumatology and Rehabilitation, School of Medicine, Cairo University, Cairo, Egypt.
Stanford Headache Center, Department of Neurology and Neurological Sciences, Center for Innovation in Global Health, Stanford University School of Medicine, Stanford, CA, USA.
J Int Med Res. 2023 May;51(5):3000605231169895. doi: 10.1177/03000605231169895.
To study the effectiveness of infliximab for the treatment of refractory central neuro-Behçet's disease.
In this systematic review and meta-analysis, the research question was designed using the 'Population, Intervention, Comparator, and Outcomes' (PICO) model and the search methodology was developed according to the PRISMA statement. The study was registered on PROSPERO. Web of Science, PubMed, and Cochrane Library databases were searched for articles published in English between January 2000 and January 2020. Data were analysed using Meta-Essentials software, version 10.12. Treatment effect size was determined by a random effects model. Interstudy heterogeneity was explored using I statistics. Cumulative meta-analysis was conducted to assess the temporal trend for accumulating evidence.
Twenty-one studies, comprising 64 patients (mean age, 38 .21 years and mean disease duration, 84.76 months) were included. Effect-size analysis showed that 93.7% of the treated patients in the analysis were responders to infliximab therapy (95% confidence interval 0.88, 0.993). There was no significant inter-study heterogeneity (I = 0%). Cumulative analysis showed accumulating evidence favoring increasing effectiveness over the last 20 years.
Infliximab showed considerable therapeutic effectiveness in the treatment of refractory neuro-Behçet's disease.
研究英夫利昔单抗治疗难治性中枢性贝赫切特病的疗效。
本系统评价和荟萃分析采用“人群、干预、比较和结局”（PICO）模型设计研究问题，并根据 PRISMA 声明制定搜索方法。研究已在 PROSPERO 上注册。检索了 2000 年 1 月至 2020 年 1 月期间发表的英文文章的 Web of Science、PubMed 和 Cochrane Library 数据库。使用 Meta-Essentials 软件，版本 10.12 对数据进行分析。采用随机效应模型确定治疗效果大小。使用 I 统计量探索研究间异质性。进行累积荟萃分析以评估累积证据的时间趋势。
纳入了 21 项研究，共 64 例患者（平均年龄 38.21 岁，平均病程 84.76 个月）。效应大小分析表明，分析中 93.7%的接受英夫利昔单抗治疗的患者为应答者（95%置信区间 0.88，0.993）。研究间无显著异质性（I=0%）。累积分析显示，过去 20 年来，支持有效性增加的证据不断增加。
英夫利昔单抗治疗难治性神经贝赫切特病具有显著疗效。
